Payment overview · 2025
General Payments
$4,829.34
223 reported records · 35 companies
Healthcare provider profile · identity verified
Michael Amoashiy, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BROOKLYN, NY · NPI 1346354982
Verified facts
What the public records show
CMS Open Payments records show Michael Amoashiy, MD received $4,829.34 in general payments during 2025 across 223 reported records.
ABBVIE INC. accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Briviact, Fycompa, Gocovri, Ingrezza, Nourianz, Nuplazid, Nurtec Odt, Qulipta, Quviviq, Rexulti, Ubrelvy, Vraylar, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 264 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Vraylar by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ongentys by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Rytary by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Fycompa by this doctor in 2024.
IDORSIA PHARMACEUTICALS US INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUVIVIQ as an associated drug or biological on 2281 records involving 1911 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Quviviq by this doctor in 2024.
KYOWA KIRIN, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NOURIANZ as an associated drug or biological on 307 records involving 305 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Nourianz by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Rexulti by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gocovri by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xadago as an associated drug or biological on 139 records involving 79 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Xadago by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Nurtec Odt by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ztlido by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $771.84 | 16.0% | 32 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $436.60 | 9.0% | 21 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $265.95 | 5.5% | 15 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $265.21 | 5.5% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $248.85 | 5.2% | 16 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $248.75 | 5.2% | 17 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $239.45 | 5.0% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $207.92 | 4.3% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $198.00 | 4.1% | 18 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $193.15 | 4.0% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$171.10 | 3.5% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $144.03 | 3.0% | 7 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$136.69 | 2.8% | 7 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $121.18 | 2.5% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $120.01 | 2.5% | 3 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $95.65 | 2.0% | 4 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $92.15 | 1.9% | 4 | 2025 |
| Validus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $86.73 | 1.8% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $78.56 | 1.6% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $70.57 | 1.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.86 | 1.4% | 3 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $69.69 | 1.4% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $62.31 | 1.3% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $59.60 | 1.2% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $58.90 | 1.2% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $58.53 | 1.2% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.52 | 1.2% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $44.75 | 0.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.49 | 0.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.90 | 0.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.47 | 0.5% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $18.06 | 0.4% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $17.96 | 0.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $15.26 | 0.3% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $14.65 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,733.68 | 219 |
| Education | $95.66 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $483.62 | 19 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $465.70 | 26 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $459.81 | 22 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $275.77 | 11 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $239.45 | 8 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $225.00 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $218.73 | 15 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $198.00 | 18 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $193.15 | 6 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $171.10 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $142.81 | 6 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $121.18 | 7 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $120.82 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $118.45 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $118.18 | 5 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $95.65 | 4 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $92.15 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $78.56 | 3 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $70.57 | 4 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $69.86 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $65.11 | 2 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $65.11 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $62.31 | 2 | 2025 |
Source payment records
|
|||||
| EQUETRO Normalized: equetro |
Drug | Validus Pharmaceuticals LLC | $62.14 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $59.60 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $58.90 | 2 | 2025 |
Source payment records
|
|||||
| NOURIANZ Normalized: nourianz |
Drug | KYOWA KIRIN, INC. | $58.53 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $56.52 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $51.45 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $48.26 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $42.49 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $41.52 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $40.95 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $30.12 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.90 | 1 | 2025 |
Source payment records
|
|||||
| RALDESY Normalized: raldesy |
Drug | Validus Pharmaceuticals LLC | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $14.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 71 | exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 70 | exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NOURIANZ nourianz |
2025 | Nourianz | 2024 | 87 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 178 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 65 | exact normalized | Medicare Part D |
| Quviviq quviviq |
2025 | Quviviq | 2024 | 66 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 234 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 264 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
71 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
264 | 41 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
145 | 23 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
154 | 19 |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| IDORSIA PHARMACEUTICALS US INC Exact reporting entity; no affiliate inference |
2025 | QUVIVIQ open payments reported associated product |
CMS Open Payments — General Payments 2281 supporting records · 1911 recipient NPIs · example record 1243392023 |
Quviviq · 2024 Exact normalized brand match · 1 Part D row |
66 | 30 |
| KYOWA KIRIN, INC. Exact reporting entity; no affiliate inference |
2025 | NOURIANZ open payments reported associated product |
CMS Open Payments — General Payments 307 supporting records · 305 recipient NPIs · example record 1222071383 |
Nourianz · 2024 Exact normalized brand match · 1 Part D row |
87 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
234 | 43 |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Xadago open payments reported associated product |
CMS Open Payments — General Payments 139 supporting records · 79 recipient NPIs · example record 1241843808 |
Xadago · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
234 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
178 | 40 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
92 | 18 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 819 | 192 |
| Escitalopram Oxalate | Escitalopram Oxalate | 708 | 137 |
| Diclofenac Sodium | Diclofenac Sodium | 587 | 186 |
| Memantine Hcl | Memantine Hcl | 478 | 86 |
| Donepezil Hcl | Donepezil Hcl | 452 | 75 |
| Primidone | Primidone | 414 | 63 |
| Lidocaine | Lidocaine | 406 | 121 |
| Quetiapine Fumarate | Quetiapine Fumarate | 381 | 81 |
| Rivastigmine | Rivastigmine | 371 | 63 |
| Meloxicam | Meloxicam | 338 | 117 |
| Trazodone Hcl | Trazodone Hcl | 320 | 73 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 287 | 49 |
| Levetiracetam | Levetiracetam | 274 | 30 |
| Ubrelvy | Ubrogepant | 264 | 41 |
| Diclofenac Epolamine | Diclofenac Epolamine | 239 | 68 |
| Rexulti | Brexpiprazole | 234 | 43 |
| Memantine Hcl Er | Memantine Hcl | 208 | 27 |
| Clonazepam | Clonazepam | 207 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 196 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 191 | 41 |
| Pregabalin | Pregabalin | 185 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 179 | 59 |
| Nurtec Odt | Rimegepant Sulfate | 178 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 173 | 33 |
| Naproxen | Naproxen | 161 | 44 |
| Sertraline Hcl | Sertraline Hcl | 160 | 24 |
| Rytary | Carbidopa/Levodopa | 154 | 19 |
| Meclizine Hcl | Meclizine Hcl | 153 | 38 |
| Ongentys | Opicapone | 145 | 23 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 141 | 47 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 140 | 29 |
| Tramadol Hcl | Tramadol Hcl | 140 | 37 |
| Propranolol Hcl | Propranolol Hcl | 138 | 37 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 136 | 22 |
| Rizatriptan | Rizatriptan Benzoate | 124 | 24 |
| Amantadine | Amantadine Hcl | 121 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 120 | 19 |
| Lamotrigine | Lamotrigine | 118 | 17 |
| Piroxicam | Piroxicam | 112 | 32 |
| Baclofen | Baclofen | 102 | 18 |
| Ztlido | Lidocaine | 92 | 18 |
| Nourianz | Istradefylline | 87 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 16 |
| Mirtazapine | Mirtazapine | 86 | 17 |
| Aptiom | Eslicarbazepine Acetate | 83 | suppressed |
| Botox | Onabotulinumtoxina | 71 | 25 |
| Briviact | Brivaracetam | 70 | 13 |
| Fluocinonide | Fluocinonide | 69 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 18 |
| Exelon | Rivastigmine | 66 | 15 |
| Quviviq | Daridorexant Hcl | 66 | 30 |
| Gralise | Gabapentin | 65 | 12 |
| Qulipta | Atogepant | 65 | 14 |
| Horizant | Gabapentin Enacarbil | 64 | 13 |
| Neupro | Rotigotine | 64 | 11 |
| Ibuprofen | Ibuprofen | 59 | 16 |
| Ingrezza | Valbenazine Tosylate | 59 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 58 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 58 | suppressed |
| Carbamazepine | Carbamazepine | 53 | 13 |
| Emgality Pen | Galcanezumab-Gnlm | 53 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | suppressed |
| Vraylar | Cariprazine Hcl | 48 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 47 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 47 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 46 | 12 |
| Topiramate | Topiramate | 46 | suppressed |
| Kesimpta Pen | Ofatumumab | 44 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 43 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 39 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 36 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 35 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 34 | suppressed |
| Fycompa | Perampanel | 34 | suppressed |
| Xadago | Safinamide Mesylate | 34 | suppressed |
| Austedo | Deutetrabenazine | 33 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 33 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 32 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Belsomra | Suvorexant | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Scopolamine | Scopolamine | 29 | suppressed |
| Levetiracetam Er | Levetiracetam | 28 | suppressed |
| Lacosamide | Lacosamide | 27 | suppressed |
| Savella | Milnacipran Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Aubagio | Teriflunomide | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 26 | suppressed |
| Celecoxib | Celecoxib | 26 | 13 |
| Dhivy | Carbidopa/Levodopa | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Furosemide | Furosemide | 24 | suppressed |
| Cambia | Diclofenac Potassium | 23 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 23 | suppressed |
| Gocovri | Amantadine Hcl | 23 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Stalevo 100 | Carbidopa/Levodopa/Entacapone | 19 | suppressed |
| Lamotrigine Er | Lamotrigine | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 11 |
| Famotidine | Famotidine | 16 | suppressed |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 13 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Nayzilam | Midazolam | 13 | suppressed |
| Vimpat | Lacosamide | 13 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Trileptal | Oxcarbazepine | 12 | suppressed |
| Cymbalta | Duloxetine Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Losartan Potassium | Losartan Potassium | 11 | suppressed |
| Trudhesa | Dihydroergotamine Mesylate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,829.34 · 223 records | ABBVIE INC. | AUSTEDO XR, Auvelity, BOTOX, BRIUMVI, Briviact, CAPLYTA, COBENFY, CREXONT, Dysport, ELYXYB - CELECOXIB, EQUETRO, FANAPT, FYCOMPA, Gocovri, INBRIJA, INGREZZA, JOURNAVX, KESIMPTA, KISUNLA, LEQEMBI, NOURIANZ, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, PERCEPT PC BRAINSENSE, PONVORY, QULIPTA, Quviviq, RALDESY, REXULTI, Symbravo, UBRELVY, UPLIZNA, VRAYLAR, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WaveWriter Alpha Prime 16, Xeomin, ZAVZPRET, ZEMBRACE SYMTOUCH, ZENPEP, ZEPOSIA, ZTLido | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error